42 articles for T Inoue
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
31
Discovery of novel 2',4'-dimethyl-[4,5'-bithiazol]-2-yl amino derivatives as orally bioavailable TRPV4 antagonists for the treatment of pain: Part 1.
Shionogi
20
Discovery of 3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-2(1H)-one derivatives as novel JAK inhibitors.
Astellas Pharma
19
Synthesis and evaluation of novel 1H-pyrrolo[2,3-b]pyridine-5-carboxamide derivatives as potent and orally efficacious immunomodulators targeting JAK3.
Astellas Pharma
43
Identification of a novel 2-pyridyl-benzensulfonamide derivative, RQ-00203078, as a selective and orally active TRPM8 antagonist.
Raqualia Pharma
17
Discovery of N-{5-[3-(3-hydroxypiperidin-1-yl)-1,2,4-oxadiazol-5-yl]-4-methyl-1,3-thiazol-2-yl}acetamide (TASP0415914) as an orally potent phosphoinositide 3-kinase inhibitor for the treatment of inflammatory diseases.
Taisho Pharmaceutical
20
Novel 1H-imidazol-2-amine derivatives as potent and orally active vascular adhesion protein-1 (VAP-1) inhibitors for diabetic macular edema treatment.
Astellas Pharma
11
Synthesis and SAR study of new thiazole derivatives as vascular adhesion protein-1 (VAP-1) inhibitors for the treatment of diabetic macular edema: part 2.
Astellas Pharma
20
Synthesis and SAR study of new thiazole derivatives as vascular adhesion protein-1 (VAP-1) inhibitors for the treatment of diabetic macular edema.
Astellas Pharma
9
Structural factors contributing to the Abl/Lyn dual inhibitory activity of 3-substituted benzamide derivatives.
Nippon Shinyaku
9
New piperidinyl- and 1,2,3,6-tetrahydropyridinyl-pyrimidine derivatives as selective 5-HT1A receptor agonists with highly potent anti-ischemic effects.
Daiichi Suntory Biomedical Research
34
New type of metalloproteinase inhibitor: design and synthesis of new phosphonamide-based hydroxamic acids.
Nippon Organon K.K.
48
A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 1. Construction of the basic framework.
Fujisawa Pharmaceutical
22
A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 4. Discovery of novel frameworks mimicking the active conformation.
Fujisawa Pharmaceutical
58
A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 3. Discovering bioisosteres of the imidazo[1,2-a] pyridine moiety.
Fujisawa Pharmaceutical
38
A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 2. Overcoming the species difference between guinea pig and man.
Fujisawa Pharmaceutical
8
Studies on selectin blocker. 1. Structure-activity relationships of sialyl Lewis X analogs.
Institute of Cancer Research
18
Novel dual inhibitors of 5-lipoxygenase and thromboxane A2 synthetase: synthesis and structure-activity relationships of 3-pyridylmethyl-substituted 2-amino-6-hydroxybenzothiazole derivatives.
Eisai
12
Synthesis and antifungal activities of novel 1,3-beta-D-glucan synthase inhibitors. Part 2.
Nippon Roche Research Center
4
Design and synthesis of biotinylated inositol 1,3,4,5-tetrakisphosphate targeting Grp1 pleckstrin homology domain.
Kumamoto Health Science University
15
Discovery of a Potent and Short−Acting Oral Calcilytic with a Pulsatile Secretion of Parathyroid Hormone
TBA
35
New aminopropandiol derivatives as orally available and short-acting calcium-sensing receptor antagonists.
Central Pharmaceutical Research Institute
31
Discovery of 3-(2-cyano-4-pyridyl)-5-(4-pyridyl)-1,2,4-triazole, FYX-051 - a xanthine oxidoreductase inhibitor for the treatment of hyperuricemia [corrected]
Fuji Yakuhin
22
Design, synthesis, and pharmacological and pharmacokinetic evaluation of 3-phenyl-5-pyridyl-1,2,4-triazole derivatives as xanthine oxidoreductase inhibitors.
Fuji Yakuhin
24
Discovery of HM-279, a Potent Inhibitor of ALK5 for Improving Therapeutic Efficacy of Cancer Immunotherapy.
Carna Biosciences
15
Discovery of tricyclic dipyrrolopyridine derivatives as novel JAK inhibitors.
Astellas Pharma
7
Rational design of non-nucleoside, potent, and orally bioavailable adenosine deaminase inhibitors: predicting enzyme conformational change and metabolism.
Fujisawa Pharmaceutical
7
Hydrophobic modifications at 1-phosphate of inositol 1,4,5-trisphosphate analogues enhance receptor binding.
The University of Tokyo
6
New 5-HT1A receptor agonists possessing 1,4-benzoxazepine scaffold exhibit highly potent anti-ischemic effects.
Suntory Biomedical Research
12
Synthesis and antifungal activities of novel 1,3-beta-D-glucan synthase inhibitors. Part 1.
Nippon Roche Research Center
15
2-Alkynyl-8-aryl-9-methyladenines as novel adenosine receptor antagonists: their synthesis and structure-activity relationships toward hepatic glucose production induced via agonism of the A(2B) receptor.
Eisai
18
Design, synthesis, and evaluation of 4,6-diaminonicotinamide derivatives as novel and potent immunomodulators targeting JAK3.
Astellas Pharma
4
Synthesis and evaluation of 1-position-modified inositol 1,4,5-trisphosphate analogs.
The University of Tokyo
7
Discovery and structural characterization of peficitinib (ASP015K) as a novel and potent JAK inhibitor.
Astellas Pharma
33
Design and Synthesis of Novel Amino-triazine Analogues as Selective Bruton's Tyrosine Kinase Inhibitors for Treatment of Rheumatoid Arthritis.
Carna Biosciences
4
Semisynthesis and biological evaluation of a cotylenin A mimic derived from fusicoccin A.
Osaka University
10
Novel caffeic acid derivatives: extremely potent inhibitors of 12-lipoxygenase.
Institute For Bio-Medical Research
11
Enhancer of zeste homolog 2 inhibitors
Glaxosmithkline Intellectual Property (No. 2)
46
mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
Vanderbilt University
2
New monomeric and dimeric uridinyl derivatives as inhibitors of chitin synthase.
Silesian University of Technology